Home 5 Clinical Diagnostics Insider 5 Biocept Believes ctDNA, CTCs Both Hold Promise in Future of Liquid Biopsy

Biocept Believes ctDNA, CTCs Both Hold Promise in Future of Liquid Biopsy

by | May 11, 2015 | Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Reimbursement-dtet

This year is poised to be a breakthrough year in the adoption of liquid biopsy technology. Biocept (San Diego) is in position to be at the forefront of this emerging market with a growing menu of tests for both circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) on the company’s proprietary OncoCEE and CEE-Selector platforms. To date, the company has released commercial tests for breast, gastric and non-small cell lung cancer and has a robust pipeline of additional tests focused on solid tumor biomarkers in colorectal, prostate, and melanoma. DTET recently spoke to Biocept CEO Michael Nall regarding recent developments at the company and the broader outlook for adoption of the liquid biopsy technology. How would you characterize the current state of clinical adoption of liquid biopsy technology? We see liquid biopsy being adopted in three phases. The first phase, where we are today, is using liquid biopsy to fulfill a true unmet medical need—when a biopsy is just not adequate or even possible to obtain. We see this in lung cancer patients most often, but it also could be in metastatic cancer for all types of solid tumors. The most common sites for metastasis are bone, brain, lung, […]

Sign up for our free weekly Lab & Pathology Insider email newsletter

Subscribe to Clinical Diagnostics Insider to view

Start a Free Trial for immediate access to this article